Ready to Light up its Synthesizer, Xeotron Prepares for DNA and Peptide Array Market | GenomeWeb

In the pond of DNA microarray providers relying on in situ synthesis, Affymetrix is still the biggest fish. But some smaller fry believe they will be able to snatch away a few juicy bites from their big brother: Xeotron, with a unique combination of photo-generated reagents, digital photolithography, and microfluidics, is poised to enter the market for custom-made DNA arrays, and is already thinking about testing new waters with its peptide arrays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.